235 related articles for article (PubMed ID: 22659388)
21. Identification of JAK2V617F in patients with polycythemia is highly correlated with conventional criteria for diagnosis of polycythemia vera.
Ganly P; Hanrahan V; Baker B; Romeril K
Am J Hematol; 2007 Jan; 82(1):80-2. PubMed ID: 16924638
[TBL] [Abstract][Full Text] [Related]
22. Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies.
Tefferi A; Vainchenker W
J Clin Oncol; 2011 Feb; 29(5):573-82. PubMed ID: 21220604
[TBL] [Abstract][Full Text] [Related]
23. Changing incidence of myeloproliferative neoplasms: trends and subgroup risk profiles in the USA, 1973-2011.
Deadmond MA; Smith-Gagen JA
J Cancer Res Clin Oncol; 2015 Dec; 141(12):2131-8. PubMed ID: 25968903
[TBL] [Abstract][Full Text] [Related]
24. Prognostic factors and models in polycythemia vera, essential thrombocythemia, and primary myelofibrosis.
Passamonti F
Clin Lymphoma Myeloma Leuk; 2011 Jun; 11 Suppl 1():S25-7. PubMed ID: 22035744
[TBL] [Abstract][Full Text] [Related]
25. Essential thrombocythemia vs. early/prefibrotic myelofibrosis: why does it matter.
Barosi G
Best Pract Res Clin Haematol; 2014 Jun; 27(2):129-40. PubMed ID: 25189724
[TBL] [Abstract][Full Text] [Related]
26. Association of TNF polymorphisms with JAK2 (V617F) myeloproliferative neoplasms in Brazilian patients.
Macedo LC; de Cesare Quintero F; Pagliari-E-Silva S; Pagnano KB; Rodrigues C; de Alencar JB; Sell AM; Visentainer JE
Blood Cells Mol Dis; 2016 Mar; 57():54-7. PubMed ID: 26852656
[TBL] [Abstract][Full Text] [Related]
27. Life, genes, and death in Ph- MPNs.
Silver RT
Blood; 2014 Oct; 124(16):2471-2. PubMed ID: 25323682
[TBL] [Abstract][Full Text] [Related]
28. Myelofibrotic transformations of polycythemia vera and essential thrombocythemia are morphologically, biologically, and prognostically indistinguishable from primary myelofibrosis.
Sangle N; Cook J; Perkins S; Teman CJ; Bahler D; Hickman K; Wilson A; Prchal J; Salama ME
Appl Immunohistochem Mol Morphol; 2014 Oct; 22(9):663-8. PubMed ID: 24897074
[TBL] [Abstract][Full Text] [Related]
29. A der(18)t(9;18)(p13;p11) and a der(9;18)(p10;q10) in polycythemia vera associated with a hyperproliferative phenotype in transformation to postpolycythemic myelofibrosis.
Larsen TS; Hasselbalch HC; Pallisgaard N; Kerndrup GB
Cancer Genet Cytogenet; 2007 Jan; 172(2):107-12. PubMed ID: 17213018
[TBL] [Abstract][Full Text] [Related]
30. [Essential thrombocythemia. Contribution of the V617F JAK2 mutation to the pathophysiology, diagnosis and outcome].
Brière J
Bull Acad Natl Med; 2007 Mar; 191(3):535-48. PubMed ID: 18072652
[TBL] [Abstract][Full Text] [Related]
31. Dkk3 levels in patients with myeloproliferative neoplasms.
Medinger M; Muesser P; Girsberger S; Skoda R; Tzankov A; Buser A; Passweg J; Tsakiris DΑ
Thromb Res; 2014 Feb; 133(2):218-21. PubMed ID: 24309205
[TBL] [Abstract][Full Text] [Related]
32. JAK2-V617F-mutated myeloproliferative neoplasms reveal different allele burden within hematopoietic cell lineages: a microdissection study of bone marrow trephine biopsies.
Kreft A; Kindler T; Springer E; Kirkpatrick CJ
Virchows Arch; 2011 Nov; 459(5):521-7. PubMed ID: 22006129
[TBL] [Abstract][Full Text] [Related]
33. [Diagnosis and treatment of BCR/ABL-negative myeloproliferative diseases--principles and rationale of CZEMP recommendations].
Schwarz J; Penka M; Campr V; Pospísilová D; Kren L; Nováková L; Bodzásová C; Brychtová Y; Cerná O; Dulícek P; Joniásová A; Kissová J; Korístek Z; Schützová M; Vonke I; Walterová L
Vnitr Lek; 2011 Feb; 57(2):189-213. PubMed ID: 21416861
[TBL] [Abstract][Full Text] [Related]
34. MicroRNA expression profile in granulocytes from primary myelofibrosis patients.
Guglielmelli P; Tozzi L; Pancrazzi A; Bogani C; Antonioli E; Ponziani V; Poli G; Zini R; Ferrari S; Manfredini R; Bosi A; Vannucchi AM;
Exp Hematol; 2007 Nov; 35(11):1708-18. PubMed ID: 17976522
[TBL] [Abstract][Full Text] [Related]
35. A phase II trial of tipifarnib in myelofibrosis: primary, post-polycythemia vera and post-essential thrombocythemia.
Mesa RA; Camoriano JK; Geyer SM; Wu W; Kaufmann SH; Rivera CE; Erlichman C; Wright J; Pardanani A; Lasho T; Finke C; Li CY; Tefferi A
Leukemia; 2007 Sep; 21(9):1964-70. PubMed ID: 17581608
[TBL] [Abstract][Full Text] [Related]
36. ADP-induced platelet aggregation and thrombin generation are increased in Essential Thrombocythemia and Polycythemia Vera.
Panova-Noeva M; Marchetti M; Russo L; Tartari CJ; Leuzzi A; Finazzi G; Rambaldi A; ten Cate H; Falanga A
Thromb Res; 2013 Jul; 132(1):88-93. PubMed ID: 23735588
[TBL] [Abstract][Full Text] [Related]
37. Prognostication in MF: from CBC to cytogenetics to molecular markers.
Zhou A; Oh ST
Best Pract Res Clin Haematol; 2014 Jun; 27(2):155-64. PubMed ID: 25189726
[TBL] [Abstract][Full Text] [Related]
38. The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia.
Bellucci S; Michiels JJ
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):381-98. PubMed ID: 16810614
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of the association between the JAK2 46/1 haplotype and myeloproliferative neoplasm in a Korean population.
Park SG; Ha JS
Int J Lab Hematol; 2015 Aug; 37(4):e91-5. PubMed ID: 25630751
[No Abstract] [Full Text] [Related]
40. Familial chronic myeloproliferative disorders: the state of the art.
Rumi E
Hematol Oncol; 2008 Sep; 26(3):131-8. PubMed ID: 18484677
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]